Recent immunotherapy approaches have focused on antibodies that block immune checkpoints, and these approaches have produced significant clinical responses in melanoma, lung cancer and kidney cancer. The authors of this Review briefly review the basic immunology underlying an antitumour immune response, and discuss the most relevant clinical trial results in these three tumour types.
- Charles G. Drake
- Evan J. Lipson
- Julie R. Brahmer
